Plain-English translation of NCT06495723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is an antibody designed to target and destroy cancer cells in a type of blood cancer called peripheral T-cell lymphoma (PTCL). The study has two parts: first, doctors will find the safest and most effective dose of this medication, and then they will test how well it works against the cancer in a larger group of patients.
Peripheral T-cell lymphoma is a difficult-to-treat cancer, and many patients do not respond well to standard chemotherapy or their cancer comes back after treatment. This trial exists to see whether this new medication can help patients whose cancer has not responded to or has returned after previous treatments.
You likely qualify if…
You likely don't qualify if…
In Part 1 (dose-finding), you will receive the medication intravenously at gradually increasing doses while doctors monitor your safety and how your body responds. In Part 2 (efficacy testing), patients will receive the medication at the safest and most effective dose identified in Part 1. Throughout the trial, you will have regular clinic visits for blood tests, imaging scans, and bone marrow biopsies to check how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
France